BR112022010223A2 - Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) - Google Patents
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp)Info
- Publication number
- BR112022010223A2 BR112022010223A2 BR112022010223A BR112022010223A BR112022010223A2 BR 112022010223 A2 BR112022010223 A2 BR 112022010223A2 BR 112022010223 A BR112022010223 A BR 112022010223A BR 112022010223 A BR112022010223 A BR 112022010223A BR 112022010223 A2 BR112022010223 A2 BR 112022010223A2
- Authority
- BR
- Brazil
- Prior art keywords
- tslp
- polypeptides
- variable domains
- immunoglobulin variable
- single immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945391P | 2019-12-09 | 2019-12-09 | |
| EP20305064 | 2020-01-27 | ||
| PCT/EP2020/085304 WO2021116182A1 (en) | 2019-12-09 | 2020-12-09 | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010223A2 true BR112022010223A2 (pt) | 2022-09-06 |
Family
ID=73793214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010223A BR112022010223A2 (pt) | 2019-12-09 | 2020-12-09 | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20210188965A1 (https=) |
| EP (1) | EP4072674A1 (https=) |
| JP (2) | JP7641968B2 (https=) |
| KR (1) | KR20220123237A (https=) |
| CN (1) | CN114980974A (https=) |
| AU (1) | AU2020400938A1 (https=) |
| BR (1) | BR112022010223A2 (https=) |
| CA (1) | CA3163910A1 (https=) |
| CO (1) | CO2022008813A2 (https=) |
| IL (1) | IL293548A (https=) |
| MX (1) | MX2022007035A (https=) |
| MY (1) | MY208649A (https=) |
| TW (2) | TW202530257A (https=) |
| WO (1) | WO2021116182A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| MX2022007035A (es) | 2019-12-09 | 2022-06-23 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. |
| AU2021350156A1 (en) | 2020-09-25 | 2023-06-08 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| IL308360A (en) * | 2021-05-30 | 2024-01-01 | Biolojic Design Ltd | Engineered dual binding antibodies and uses thereof |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| US20240117038A1 (en) * | 2022-07-18 | 2024-04-11 | Ablynx N.V. | Cx3cr1-binding compounds, methods and uses thereof |
| CN118005784A (zh) * | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| EP4435005A1 (en) | 2023-03-24 | 2024-09-25 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| AU2024247861A1 (en) | 2023-03-24 | 2025-11-06 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| CN121816362A (zh) * | 2023-06-22 | 2026-04-07 | 派拉冈医疗公司 | 结合白细胞介素13和tslp或tslpr的抗体及其使用方法 |
| AU2024334289A1 (en) | 2023-08-25 | 2026-04-09 | Proteologix Us Inc. | Anti-il-13 multispecific antibody constructs and uses thereof |
| AR134102A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS |
| WO2025209486A1 (en) * | 2024-04-02 | 2025-10-09 | Keymed Biosciences (Chengdu) Co., Ltd. | Antibodies targeting il-13 and tslp and uses thereof |
| WO2026041740A1 (en) | 2024-08-21 | 2026-02-26 | Sanofi | Treatment of high-risk asthma by blocking il-13 and tslp |
| WO2026055143A2 (en) * | 2024-09-03 | 2026-03-12 | Attovia Therapeutics, Inc. | Il13-binding polypeptides and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| AU2007293614A1 (en) * | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| JP5059119B2 (ja) * | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗ｔｓｌｐ抗体 |
| KR20110092328A (ko) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Ｉｌ-13에 결합하는 리간드 |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| LT3374392T (lt) | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| CA3003777A1 (en) * | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1/ctla4 binders |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| KR20180080337A (ko) * | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| EP3426278B1 (en) * | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
| BR112019010061A2 (pt) * | 2016-11-16 | 2019-08-13 | Ablynx Nv | polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta |
| RU2022101604A (ru) | 2016-12-07 | 2022-03-29 | Аблинкс Нв | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| IL267897B2 (en) | 2017-01-17 | 2025-02-01 | Ablynx Nv | Improved serum albumin binders |
| JP7219220B2 (ja) | 2017-01-17 | 2023-02-07 | アブリンクス エン．ヴェー． | 改善された血清アルブミン結合剤 |
| KR20210005872A (ko) * | 2018-03-28 | 2021-01-15 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CN109887553B (zh) * | 2019-01-29 | 2021-01-26 | 杭州纽安津生物科技有限公司 | 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| MX2022007035A (es) * | 2019-12-09 | 2022-06-23 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. |
-
2020
- 2020-12-09 MX MX2022007035A patent/MX2022007035A/es unknown
- 2020-12-09 WO PCT/EP2020/085304 patent/WO2021116182A1/en not_active Ceased
- 2020-12-09 TW TW113137609A patent/TW202530257A/zh unknown
- 2020-12-09 MY MYPI2022002971A patent/MY208649A/en unknown
- 2020-12-09 AU AU2020400938A patent/AU2020400938A1/en active Pending
- 2020-12-09 CN CN202080085549.9A patent/CN114980974A/zh active Pending
- 2020-12-09 TW TW109143498A patent/TWI861302B/zh active
- 2020-12-09 EP EP20823785.9A patent/EP4072674A1/en active Pending
- 2020-12-09 US US17/115,906 patent/US20210188965A1/en not_active Abandoned
- 2020-12-09 CA CA3163910A patent/CA3163910A1/en active Pending
- 2020-12-09 KR KR1020227023385A patent/KR20220123237A/ko active Pending
- 2020-12-09 BR BR112022010223A patent/BR112022010223A2/pt unknown
- 2020-12-09 IL IL293548A patent/IL293548A/en unknown
- 2020-12-09 JP JP2022534664A patent/JP7641968B2/ja active Active
-
2021
- 2021-11-19 US US17/530,727 patent/US12384840B2/en active Active
- 2021-11-19 US US17/530,800 patent/US11840566B2/en active Active
- 2021-11-19 US US17/530,850 patent/US12492248B2/en active Active
-
2022
- 2022-06-24 CO CONC2022/0008813A patent/CO2022008813A2/es unknown
-
2025
- 2025-02-20 JP JP2025025563A patent/JP2025081540A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021116182A1 (en) | 2021-06-17 |
| US12492248B2 (en) | 2025-12-09 |
| US20220177565A1 (en) | 2022-06-09 |
| JP2025081540A (ja) | 2025-05-27 |
| JP2023504914A (ja) | 2023-02-07 |
| EP4072674A1 (en) | 2022-10-19 |
| IL293548A (en) | 2022-08-01 |
| TW202136302A (zh) | 2021-10-01 |
| MY208649A (en) | 2025-05-22 |
| US20210188965A1 (en) | 2021-06-24 |
| CA3163910A1 (en) | 2021-06-17 |
| CO2022008813A2 (es) | 2022-07-19 |
| KR20220123237A (ko) | 2022-09-06 |
| CN114980974A (zh) | 2022-08-30 |
| JP7641968B2 (ja) | 2025-03-07 |
| MX2022007035A (es) | 2022-06-23 |
| US11840566B2 (en) | 2023-12-12 |
| US20220177566A1 (en) | 2022-06-09 |
| TW202530257A (zh) | 2025-08-01 |
| AU2020400938A1 (en) | 2022-07-28 |
| TWI861302B (zh) | 2024-11-11 |
| US12384840B2 (en) | 2025-08-12 |
| US20220177564A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010223A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) | |
| MX2022006881A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. | |
| AR120698A1 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp | |
| Nicolaidou et al. | Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation | |
| ZA202107047B (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| Chen et al. | Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| BR112022001902A2 (pt) | Proteína biespecífica de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica e método para a produção da proteína biespecífica de ligação ao antígeno | |
| MX2024010771A (es) | Anticuerpos multiespecificos y usos de estos. | |
| MX2021003608A (es) | Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente. | |
| MX394165B (es) | Anticuerpos anti-receptor ccr7 humanizados. | |
| BR112022004986A2 (pt) | Anticorpos anti-tnfr2 e métodos de uso | |
| CO2023002989A2 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y ox40l | |
| MX2024003355A (es) | Anticuerpos anti-cd3. | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
| BR112022009799A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| Al‐Samadi et al. | IL‐17 C and its receptor IL‐17 RA/IL‐17 RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| UY38672A (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
| Hauerslev et al. | Muscle atrophy reversed by growth factor activation of satellite cells in a mouse muscle atrophy model | |
| CR20240378A (es) | Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024023752-0 PROTOCOLO 870240097416 EM 13/11/2024 18:06. |